Report Overview

China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 9.2% during the forecast period.

PNH is a chronic, progressive, debilitating, and life-threatening ultra-rare blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells). The average age of onset in the early 30s. Chinas Incidence rate is 2.7/100,000 persons and the prevalence rate varies between provinces (0.8 to 1.4/100,000 persons) in China.



Market Drivers

The China is growing market for paroxysmal nocturnal hemoglobinuria (PNH) disease due to rise in a number of blood and bone marrow related disorders and increase in geriatric population (12.57% in 2019 in China) are the key factors which drive the market growth of PNH treatment market. In addition to these, the emergence of biologics, increase in Chinas incidence rate (2.7/100,000 persons), increase in Chinas prevalence rate (0.8 to 1.4/100,000 persons) and adoption of novel therapeutics are further pushing the market growth.

However, adverse effects associated with currently available treatments, increase in the cost of medical equipment, specifically surgical equipment required for stem cell transformation are some factors that restrain market growth of PNH.